Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,221 to 4,240 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Fluid Restriction Group vs Standard-care: All-cause Mortality at 1-year After Randomisation | 385 of 750 383 of 767 | 1.4 points -3.6 to 6.4 | 1,517 | NCT03668236 The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial |
| Primary Enrollment Group vs 38 mm Length Sub-Study: serious adverse events | 509 of 1,402 71 of 114 | -26.0 points -34.7 to -16.5 | 1,516 | NCT00726453 The Medtronic RESOLUTE US Clinical Trial |
| Olive Oil Capsule vs Omega-3 Fatty Acid Capsules: Any First Post-op Atrial Fibrillation or Flutter (AF) | 233 of 758 227 of 758 | 0.8 points -3.8 to 5.4 | 1,516 | NCT00970489 Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation |
| Olive Oil Capsule vs Omega-3 Fatty Acid Capsules: serious adverse events | 147 of 758 136 of 758 | 1.5 points -2.5 to 5.4 | 1,516 | NCT00970489 Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation |
| Restrictive Fluids vs Liberal Fluids: Development of ARDS | 19 of 757 20 of 758 | -0.1 points -1.8 to 1.5 | 1,515 | NCT03434028 Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis |
| Boostrix Group vs Adacel Group: Number of Subjects With Anti-diphtheria (Anti-D) Antibody Concentrations Greater Than or Equal to (≥) Protocol Specified Cut-off | 967 of 1,010 489 of 504 | -1.3 points -3.1 to 0.9 | 1,514 | NCT00489970 Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9 |
| Information vs Usual Care: Advance Care Planning Billing | 23 of 770 11 of 743 | 1.5 points -0.0 to 3.1 | 1,513 | NCT04852055 Effect of an Advance Care Planning Intervention |
| Information vs Usual Care: Hospitalization | 113 of 770 110 of 743 | -0.1 points -3.7 to 3.4 | 1,513 | NCT04852055 Effect of an Advance Care Planning Intervention |
| cSBA - New England, USA vs Control - New England, USA: Any Risky Riding or Driving at 3 Months - New England, USA | 88 of 758 150 of 754 | -8.3 points -11.9 to -4.6 | 1,512 | NCT00227877 Screening and Brief Advice to Reduce Teen Substance Use |
| Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: S-Ferritin Concentration of ≥100 ng/mL and Transferrin Saturation (TSAT) of 20-50% at Any Time From Week 1 to Week 8 | 873 of 1,012 388 of 500 | 8.7 points 4.6 to 13.0 | 1,512 | NCT02940860 Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease |
| Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8 | 32 of 1,011 4 of 500 | 2.4 points 0.8 to 3.7 | 1,511 | NCT02940860 Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease |
| Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8 | 484 of 1,009 225 of 502 | 3.1 points -2.2 to 8.4 | 1,511 | NCT02940886 Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA) |
| Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8 | 687 of 1,009 340 of 502 | 0.4 points -4.6 to 5.4 | 1,511 | NCT02940886 Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA) |
| QMF149 Twisthaler® 500/400 vs Mometasone Twisthaler®: Patients With Asthma Exacerbations That Required Treatment With Systemic Corticosteroids | 124 of 749 171 of 759 | -6.0 points -10.0 to -2.0 | 1,508 | NCT00941798 Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma |
| QMF149 Twisthaler® 500/400 vs Mometasone Twisthaler®: Cumulative Incidence of the First Serious Asthma Exacerbation Resulting in Hospitalization, Intubation or Death. | 2 of 749 6 of 759 | -0.5 points -1.5 to 0.3 | 1,508 | NCT00941798 Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma |
| QMF149 Twisthaler® 500/400 vs Mometasone Twisthaler®: Number of Patients With at Least One Asthma Worsening Post-baseline | 533 of 749 637 of 759 | -12.8 points -16.9 to -8.6 | 1,508 | NCT00941798 Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma |
| QMF149 Twisthaler® 500/400 vs Mometasone Twisthaler®: serious adverse events | 30 of 749 44 of 759 | -1.8 points -4.0 to 0.4 | 1,508 | NCT00941798 Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma |
| 150 µg Corifollitropin Alfa vs 200 IU recFSH: serious adverse events | 35 of 755 30 of 751 | 0.6 points -1.5 to 2.7 | 1,506 | NCT00696800 A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787) |
| Standard of Care Plus (SCP) vs Collaborative Care/Stepped Care (CC/SC): Number of Participants With Controlled Blood Pressure | 462 of 750 442 of 754 | 3.0 points -2.0 to 7.9 | 1,504 | NCT02674464 Reducing Inequities in Care of Hypertension, Lifestyle Improvement for Everyone (RICH LIFE Project) |
| Intervention vs Control: deaths from any cause | 8 of 1,000 4 of 503 | 0.0 points -1.3 to 0.9 | 1,503 | NCT01800201 Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong) |
Code
curl "https://conductscience.org/api/comparisons/v1?page=212"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=212
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03668236-0de99219",
"title": "Fluid Restriction Group vs Standard-care: All-cause Mortality at 1-year After Randomisation",
"summary": "385 of 750 against 383 of 767; risk difference 1.4 points, 95% interval -3.6 to 6.4; NCT03668236, The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial",
"record": "/library/comparisons/NCT03668236-0de99219",
"nct_id": "NCT03668236",
"kind": "outcome",
"participants": 1517,
"risk_difference": {
"value": 0.01398522381573225,
"lower": -0.03625425849769667,
"upper": 0.06412353122718675
},
"group_1": "385 of 750",
"group_2": "383 of 767",
"difference": "1.4 points",
"interval": "-3.6 to 6.4",
"trial_title": "The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial"
},
{
"id": "NCT00726453-sae",
"title": "Primary Enrollment Group vs 38 mm Length Sub-Study: serious adverse events",
"summary": "509 of 1402 against 71 of 114; risk difference -26.0 points, 95% interval -34.7 to -16.5; NCT00726453, The Medtronic RESOLUTE US Clinical Trial",
"record": "/library/comparisons/NCT00726453-sae",
"nct_id": "NCT00726453",
"kind": "serious-adverse-events",
"participants": 1516,
"risk_difference": {
"value": -0.2597542358034888,
"lower": -0.3469436696170688,
"upper": -0.1646626056137923
},
"group_1": "509 of 1,402",
"group_2": "71 of 114",
"difference": "-26.0 points",
"interval": "-34.7 to -16.5",
"trial_title": "The Medtronic RESOLUTE US Clinical Trial"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=213",
"request_id": "SWAYlhclMjYEG_Vk"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant